14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
EVMN vs DNA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
EVMN Overall Winner
6-Pillar Tally: EVMN 3 – 2 DNA (1 Tie)
Matrix Metrics: EVMN 4 – 4 DNA
As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over Ginkgo Bioworks Holdings, Inc. (DNA) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). EVMN carries a Unified Composite Score of 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin), whereas DNA carries 56.0/100 (HOLD) at $8.50 (N/M Forward P/E, -202.5% operating margin).
Composite vs. Pillar Nuance: While DNA currently prints a higher short-term Unified Composite Score (56.0/100 HOLD vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -202.5% operating margin) and revenue trajectory (+0.0% vs. -5.7% YoY).
Technical & Structure Timing Caution: EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2); meanwhile DNA is in a Breakdown options structure phase (RSI 41.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $315.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
DNA Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $623.0M market capitalization and -202.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ EVMN vs DNA Key Questions & Quantitative Answers
As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over Ginkgo Bioworks Holdings, Inc. (DNA) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). EVMN carries a Unified Composite Score of 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin), whereas DNA carries 56.0/100 (HOLD) at $8.50 (N/M Forward P/E, -202.5% operating margin). Composite vs. Pillar Nuance: While DNA currently prints a higher short-term Unified Composite Score (56.0/100 HOLD vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -202.5% operating margin) and revenue trajectory (+0.0% vs. -5.7% YoY). Technical & Structure Timing Caution: EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2); meanwhile DNA is in a Breakdown options structure phase (RSI 41.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DNA leads the Growth & Scale pillar: EVMN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DNA at -5.7% YoY revenue growth and +0.0% YoY earnings growth on $131M TTM revenue (69.8% gross margin, -202.5% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), EVMN cumulative revenue shifted +0.0% while DNA shifted +240.0%. In operating R&D and SG&A reinvestment, EVMN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DNA.
DNA screens cheaper on headline valuation multiples. EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVMN (-69.5% ROE) versus DNA (-58.2% ROE) capital efficiency.
In options market volatility and institutional positioning, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk). By comparison, DNA carries 119.2% implied volatility (34th %ile, Balanced (25th–60th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.14β · 152% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.